UY34488A - ANTIBODIES TARGETED AT THE RECEIVER OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN III AND DOMAIN IV OF HER3 - Google Patents

ANTIBODIES TARGETED AT THE RECEIVER OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN III AND DOMAIN IV OF HER3

Info

Publication number
UY34488A
UY34488A UY0001034488A UY34488A UY34488A UY 34488 A UY34488 A UY 34488A UY 0001034488 A UY0001034488 A UY 0001034488A UY 34488 A UY34488 A UY 34488A UY 34488 A UY34488 A UY 34488A
Authority
UY
Uruguay
Prior art keywords
her3
targeted
domain
receiver
growth factor
Prior art date
Application number
UY0001034488A
Other languages
Spanish (es)
Inventor
Elis Winfried
Ettenberg Seth
Andrew Paul Garner
Christian Carsten Silvester Kunz
Haubst Nicole
Elizabeth Anne Reisinger Sprague
Sheng Qing
Huet Heather
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY34488A publication Critical patent/UY34488A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

No escanear figuras.
UY0001034488A 2011-12-05 2012-12-04 ANTIBODIES TARGETED AT THE RECEIVER OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN III AND DOMAIN IV OF HER3 UY34488A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05

Publications (1)

Publication Number Publication Date
UY34488A true UY34488A (en) 2013-07-31

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034488A UY34488A (en) 2011-12-05 2012-12-04 ANTIBODIES TARGETED AT THE RECEIVER OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN III AND DOMAIN IV OF HER3

Country Status (16)

Country Link
EP (1) EP2788381A2 (en)
JP (1) JP2015500830A (en)
KR (1) KR20140099315A (en)
CN (1) CN104093742A (en)
AR (1) AR089085A1 (en)
AU (1) AU2012349739A1 (en)
BR (1) BR112014013495A8 (en)
CA (1) CA2857939A1 (en)
EA (1) EA201491120A1 (en)
IL (1) IL232950A0 (en)
IN (1) IN2014CN04374A (en)
MX (1) MX2014006731A (en)
SG (1) SG11201402784WA (en)
TW (1) TW201331225A (en)
UY (1) UY34488A (en)
WO (1) WO2013084151A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913289TA (en) * 2014-02-28 2020-02-27 Merus Nv Antibody that binds erbb-2 and erbb-3
JP6771385B2 (en) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ Bispecific antibody and pharmaceutical composition
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
CN104530237B (en) * 2014-12-31 2017-09-05 百泰生物药业有限公司 Anti- Her1 therapeutic antibodies
EP3912998A3 (en) 2015-10-23 2022-02-23 Merus N.V. Binding molecules that inhibit cancer growth
JP6729926B2 (en) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ErbB3 activation signal transduction inhibitor and method for screening the same
US11008402B2 (en) 2016-09-15 2021-05-18 Universitat Stuttgart Antigen binding protein against HER3
KR101923641B1 (en) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 Anti-HER3 antibody and composition for preventing or treating cancer comprising the same
JP2020511993A (en) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells carrying the NRG1 fusion gene
WO2019031965A1 (en) 2017-08-09 2019-02-14 Merus N.V. Antibodies that bind egfr and cmet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (en) * 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
WO2010127181A1 (en) * 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
CN105999263B (en) * 2009-11-13 2021-06-29 第一三共欧洲有限公司 Materials and methods for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases
RU2568051C2 (en) * 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. ANTI-ErbB3 ANTIBODIES
TW201302793A (en) * 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
DK2707391T3 (en) * 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3

Also Published As

Publication number Publication date
SG11201402784WA (en) 2014-06-27
EA201491120A1 (en) 2015-07-30
IL232950A0 (en) 2014-07-31
BR112014013495A2 (en) 2017-06-13
TW201331225A (en) 2013-08-01
CN104093742A (en) 2014-10-08
WO2013084151A2 (en) 2013-06-13
AR089085A1 (en) 2014-07-30
WO2013084151A3 (en) 2014-01-03
EP2788381A2 (en) 2014-10-15
IN2014CN04374A (en) 2015-09-04
KR20140099315A (en) 2014-08-11
CA2857939A1 (en) 2013-06-13
AU2012349739A1 (en) 2014-06-26
JP2015500830A (en) 2015-01-08
MX2014006731A (en) 2015-06-04
BR112014013495A8 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
UY34488A (en) ANTIBODIES TARGETED AT THE RECEIVER OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN III AND DOMAIN IV OF HER3
UY34486A (en) ANTIBODIES TARGETED AT THE RECEPTOR OF EPIDERMAL GROWTH FACTOR 3 (HER3) TARGETED AGAINST DOMAIN II OF HER3
UY34456A (en) ANTI-IL-36R ANTIBODIES
UY34487A (en) ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEIVER 3 (HER3)
CL2012002979A1 (en) N3-substituted-n1-sulfonyl-5-fluorpyrimidinone derivatives.
UY34813A (en) ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
MX342240B (en) Anti-fgfr4 antibodies and methods of use.
UY34206A (en) INTERLEUCINE MONOCLONAL ANTIBODY-31
UY34582A (en) ANTI-CXCR3 ANTIBODIES
UY34411A (en) IMMUNO LINKERS AGAINST SCLEROSTINE
UY34472A (en) MODIFIED DERIVATIVES OF 4-PHENYL-PYRIDINE
UY34721A (en) ANTI-HLA-B * 27 ANTIBODIES AND USES OF THESE.
MX336001B (en) Anti-axl antibodies and methods of use.
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
MX2014002053A (en) Anti-mcsp antibodies.
MX2018014178A (en) Anti-fgfr2 antibody.
MX2013001473A (en) Antibodies against il-18r1 and uses thereof.
MX354303B (en) Anti-biotin antibodies and methods of use.
MX2012011829A (en) Anti-polyubiquitin antibodies and methods of use.
MX357675B (en) Anti-jagged anitbodies and methods of use.
MY168248A (en) Next-instruction-type field
UY34286A (en) IMPROVED VACCINE DIAGNOSIS
UY34658A (en) Plants with enhanced growth properties
UY34497A (en) Crystalline forms of [(S) -1-carbamoyl-2- (phenyl-pyrimidin-2-yl-amino) -ethyl] -amide of 2- (2-methylamino-pyrimidin-4-yl) -1H-indole- 5-carboxylic.
UY33207A (en) THIAZOLIDIN PREPARATION METHODS

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020